MaaT Pharma (MAAT) advances US development talks as funding remains critical
FDA feedback supports the French biotech’s next preparatory steps, but a first human study remains conditional.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
MaaT Pharma reported constructive FDA feedback after a pre-IND interaction concerning MaaT034, its microbiome programme for solid tumours. The discussions addressed manufacturing and nonclinical matters, with the company saying no additional nonclinical studies were anticipated to support administration safety.
This is preparatory regulatory engagement, not permission to begin a clinical trial. MaaT plans further IND-enabling work and a Type C meeting focused on its proposed clinical development plan and first-in-human study design.
The financing gap is particularly relevant. The company said a first human study could begin in late 2027, subject to regulatory clearances and appropriate funding, while its estimated cash runway extends only to December 2026. It is exploring investor financing and strategic partnerships.
The update gives potential partners greater visibility into the US development route. It does not remove the need to fund the work between regulatory planning and clinical execution. For investors, the scientific opportunity and the balance-sheet timetable must therefore be considered together when assessing the value of this milestone.